Open AccessGasser cell: A biomarker of response to enzyme replacement therapy in patients with mucopolysaccharidosis type VI
Author(s) -
Márcio Antonio Wanderley de Melo,
Marcelo Soares Kertenetzky,
Cristina Magalhães da Silveira,
Maíra Magalhães Ribeiro,
Gabriela da Silva Arcanjo,
Antonio R. Lucena-Araújo,
Marcos André Cavalcanti Bezerra,
Maria Tereza Cartaxo Muniz,
María Auxiliadora de Queiroz Cavalcanti
Publication year - 2021
Publication title -
research, society and development
Language(s) - English
Resource type - Journals
ISSN - 2525-3409
DOI - 10.33448/rsd-v10i5.14726
Subject(s) - enzyme replacement therapy , mucopolysaccharidosis type ii , biomarker , mucopolysaccharidosis , medicine , disease , chemistry , cancer research , pathology , biochemistry
The mucopolysaccharidosis (MPS) type VI is a rare lysosomal storage disease presenting leukocyte inclusions (Alder-Reilly anomaly) and lymphocytes with metachromatic inclusion surrounded by clear spaces, Gasser cells. Currently, an enzyme replacement therapy (ERT) with galsulfase is used to treat MPS type VI. This study evaluated 14 patients with MPS type VI performed cell counts Gasser before and after six months from the beginning of ERT. It was observed an average of 12.7% cells per patient, and after six months was found complete cell Gasser disappearance, proving to be an effective biomarker of response to ERT.